Quantum BioPharma Ltd. has successfully completed its Phase 1 clinical trial of Lucid-21-302, also known as Lucid-MS, a novel compound aimed at treating multiple sclerosis (MS). A safety review ...
Vaccination is vital for MS patients, especially those on immunosuppressive therapies, to prevent severe COVID-19 outcomes. The review confirms vaccine safety and efficacy, even for patients on ...
Quantum Biopharma Ltd. (NASDAQ:QNTM) announced on Tuesday that its subsidiary Huge Biopharma Australia has received the clinical study report for a Phase 1, randomized, double-blind, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results